Aim:To develop a method for rapid and sensitive simultaneous determination of the hydrophilic and lipophilic active components in Salvia miltiorrhiza tablets. Methods:RP-HPLC condition was established to separate danshensu,salvianolic acid B,cryptotanshinone and tanshinone ⅡA from each other on the Diamonsil C18(250 mm×4.6 mm ID,5 μm)column with the mobile phase consisted of methanol and 0.5% formic acid in gradient elution. Results:The four active components had good linearity. The average recoveries ranged between 96.63% to 100.3% with RSDs of less than 2%. Conclusion:The method appeared to be precise and accurate for the simultaneous determination of the four active components in Salvia miltiorrhiza Bunge tablets within 35 min.

Objective:To explore the clinical therapeutic effect of simvastatin combined cyclic adenosine monophos-phate on coronary heart disease (CHD)with chronic heart failure (CHF)and levels of serum-related factors.Meth-ods:A total of 78 CHD patients with CHF hospitalized in our hospital from Jan 2011 to Jan 2012 were selected. They were randomly and equally divided into simvastatin group and combined treatment group using number table, both groups received routine treatment,simvastatin group received simvastatin in addition, while combined treat-ment group received cyclic adenosine monophosphate based on simvastatin group.Therapeutic effect,changes of cardiac function indexes and serum factor levels were compared between two groups before and after treatment.Re-sults:The total effective rate of combined treatment group (92.31%)was significantly higher than that of simvasta-tin group (71.79%),P<0.05;compared with before treatment and simvastatin after treatment,there were signifi-cant rise in left ventricular ejection fraction [LVEF,(33.54±3.34)%,(43.41±3.23)% vs.(55.21±3.45)%] and transmitral early/late diastolic peak flow velocity [E/A,(0.63±0.11),(0.70±0.15)vs.(1.01±0.21)],and significant reductions in levels of brain natriuretic peptide [BNP,(536.74±21.41)ng/ml,(117.23±11.57)ng/ml vs.(78.20±10.92)ng/ml]and C reactive protein [CRP,(24.00±2.34)mg/L,(17.01±1.09)mg/L vs.(8.28± 0.81)mg/L]in combined treatment group,P<0.05~<0.01.Conclusion:Simvastatin combined cyclic adenosine monophosphate possess significant therapeutic effect on chronic heart failure of coronary heart disease,it can signif-icantly improve cardiac function and serum factor levels in CHD patients with chronic heart failure,and possess good clinical application value.

Objective To explore the effect of valasartan, an angiotensin Ⅱ type 1 (AT 1) receptor antagonist, on the plasma levels of calcitonin gene-related peptide (CGRP) in patients with essential hypertension. Methods 29 outpatients with essential hypertension were treated with valasartan 80mg/day for 6 weeks. 28 age-matched normal blood pressure people were taken as controls. The plasma levels of CGRP were measured in all patients before and after treatment and in controls. Results The plasma levels of CGRP in hypertensive patients were significantly lower than those in controls (minimal value: 0.00 vs 39.95pg/ml; maximal value: 24.07 vs 155.59pg/ml; P

Objective:To investigate the anti-tumor effect of tetrandrine on human liver cancer cell line 7402 in vitro.Effects of tetrandrine on proliferation and apoptosis of human liver cancer cell 7402 were observed.Methods:The effects of tetrandrine on proliferation of 7402 cells was observed by MTT assay and clonogenic assay.Apoptosis was observed by acridine orange(AO)/ethidium bromide(EB) Fluorescent staining?DNA gel electrophoresis and flow cytometry,and the expression of apoptosis related gene was analyzed by immunohistochemical staining method.Results:Tetrandrine inhibits the proliferation of 7402 cells in a dose dependent manner and induces apoptosis.Immunohistochemical staining showed that the expression of Bcl-2 was decreased and the expression of Bax was increasd in 7402 cells treated with tetrandrine.Conclusion:Tetrandrine inhibits the proliferation of 7402 in the dose dependent manner,and induces apoptosis.The antitumor effect of tetrandrine may be due to the regulation of the expressions of Bcl-2 and Bax.

Analyze the problems of medical insurance real-time settlement in outpatient department.Explore the situation of stringent management of health medical insurance agencies,accuracy of the information,significant increasing costs that medical insurance agencies refused to pay and severe environment to doctors.And management strategy such as regulating doctors' behavior strictly,upgrading hospital information systems,increasing hospital staff to excavate the hospital potential and publicizing the new policy of medical insurance comprehensively.

Humans ; Myofibroma ; pathology ; Stomach Neoplasms ; pathology

In this paper, the fluorogenic property of vindoline was exploited and, as a probe, used to analyze the interaction of vindoline with HSA by fluorescence and absorption spectra in combination with molecular modeling under a simulated physiological conditions. The evidences from synchronous fluorescence and absorption spectroscopes showed the effect of vindoline on the microenvironment around HSA in aqueous solution. Data obtained by the fluorescence spectroscopy indicated that binding of vindoline with HSA leads to dramatic enhancement of the fluorescence emission intensity. The binding constants and the number of binding sites between vindoline and HSA at different temperatures (303, 310 and 317 K) were calculated according to the data obtained from fluorescence titration. Molecular docking was performed to reveal the possible binding mode or mechanism and suggested that vindoline can bind strongly to HSA. It is considered that vindoline binds to HSA mainly by a hydrophobic interaction and there are four hydrogen bonds interactions between the drug and the residues Ala291, Arg222, Arg218 and Lys195, separately. Fluorescent displacement measurements confirmed that vindoline bind HSA on site II. The thermodynamic parameters obtained (the enthalpy change deltaH0 and the entropy change deltaS0 were calculated to be -10.30 kJ x mol(-1) and 79.98 J x mol(-1) x K(-1), respectively, according to the Van't Hoff equation) suggested that hydrophobic and electrostatic interaction is the predominant intermolecular forces stabilizing the complex.

Objective To explore the function of placental trophoblast cell apoptosis on the pathogenetic mechanism of pregnancy induced hypertension (PIH). Methods Apoptosis of trophoblast cells in 20 cases of PIH(PIH group) and in 10 cases of normal pregnancy (control group) were directly observed using the terminal-deoxynucleotidyl transferase mediated d-UTP nick end labeling (TUNEL) method. Apoptosis gene expression patterns were screened with gene chip provided by Poxing Company, Shanghai. Standards for differently expressed genes were: (1) An absolute value of the natural logarithm of cy5(PIH group)/cy3(control group) greater than 0.69 with a difference of signal of cy5 2 times over that of cy3. (2) The signal value either cy3 or cy5 must be greater than 800. Results (1) TUNEL test showed that the number of trophoblast cells apoptosis per ten thousand ?m 2 was 1.584 in the PIH group and 0.032 in the control group with significant difference between the two groups (P

ObjectiveTo investigate application value of parametric image processing in contrastenhanced ultrasound imaging in diagnosis of ovarian masses. MethodsFifty cases with ovarian masses underwent routine ultrasound and contrast-enhanced ultrasound imaging using a new dedicated parametric image processing software SonoLiver to analyze patterns of vascular formation and blood stream perfusion in the ovarian mass tissues on a digital video recorder in real time, compare their morphological characteristics of time-intensity curve (TIC) and dynamic vascular patterns (DVP) curve, and analyze quantitatively all indicators generated by SonoLiver.ResultsIn ultrasound imaging of the 50 cases, there were 24 cases (86％) displaying mainly blue lowly-enhanced imaging in those with benign masses and 15 cases (68％)displaying mainly red highly-enhanced imaging in those with malignant masses, with statistical significance (P ＜0. 01 ). There was significantly different characteristics of TIC and DVP between patients with benign and malignant masses. In 23 cases with benign masses, their DVP were significantly higher above the baseline than in those with malignant ones ( P = 0. 000), and in 15 cases with malignant lesions, their DVP were much shorter below the baseline than in those with benign ones, with statistical significance (P ＜0.05). The intensity of contrast medium, the time to reach its peak intensity and average transit time were all significantly higher in those with malignant masses than in those with benign ones (all P ＜ 0. 05 ). But, no statistical difference in the time of initial increasing between the two groups was found (P ＞ 0. 05). ConclusionsThere is significant difference in TIC and DVP of ultrasound imaging between benign and malignant masses, which if combined with contrast enhanced ultrasound parametric image processing can provide a more visualized quantitative information of benign and malignant ovarian masses with SonoLiver software.

AIM: To establish an LC-MS/MS method for determination of evodiamine concentration in rat plasma and to study its pharmacokinetic profile in rats. METHODS: Six rats were administrated (i.g.) evodiamine at the dose of 100 mg/kg. Blood samples were collected from eye socket. Evodiamine concentration in rat plasma was determined by LC-MS/MS method. The pharmacokinetic parameters were calculated using DAS program. RESULTS: A good linear relationship was obtained in the concentration range (0.2-50.0 ng/mL) studied (r2=0.9997). Average recoveries ranged from 96.12% to 99.46%. Intra-and inter-day relative standard deviations were 4.61%-13.51% and 5.65%-11.49%, respectively. The main pharmacokinetic parameters of evodiamine were as follows: Cmax (5.3±1.5) ng/mL; tmax (22±8) min; t1/2 (451±176) min. CONCLUSION: A selective and sensitive liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the quantification of evodiamine in rat plasma is developed and validated. This method is successfully applied for the pharmacokinetic studies of evodiamine in rats.